par Ickx, Brigitte 
;Van Der Linden, Philippe
Référence STV. Sang thrombose vaisseaux, 14, 7, page (408-416)
Publication Publié, 2002-09
;Van Der Linden, Philippe Référence STV. Sang thrombose vaisseaux, 14, 7, page (408-416)
Publication Publié, 2002-09
Article révisé par les pairs
| Résumé : | Used for the treatment of hypovolemia, colloid solutions have actually supplanted albumin solutions. These solutions of macromolecules include dextrans, gelatins, and hydroxyethyl starches (HES). All these synthetic colloids interfere with the physiologic mechanism of haemostasis causing a non specific alteration of coagulation correlated to the amount of haemodilution and associated with specific effects due to the macromolecules. However, these effects on haemostasis have little clinical impact provided safety measures are observed. These consist of strict observation of the maximal daily dosage and of the duration of treatment. Caution should be taken also in patients presenting with haemostasis abnormalities and with haemodilution greater than 30% of patient's blood volume. Albumin could then be chosen for plasma expansion. Among the different types of macromolecules solutions, gelatins and low or medium molecular weight HES (LMWHES) have less effect on blood loss than dextrans or high molecular weight HES (HMWHES). The recently developed HES, 130/0.4 (Voluven®) has less impact on haemostasis as compared with gelatins, increasing the authorized volume of administration to 50 mL/kg per day. |
